Joan Carles
Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program
Saad F, Carles J, Seger M, Reeves J, Wirth M, Miller K, Nilsson S, O'Sullivan J, Keizman D, Heinrich D, Gillessen Sommer S, Heidenreich A. Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program. Clin Genitourin Cancer 2019; 17:348-355.e5.
May 31, 2019Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program
May 31, 2019Clin Genitourin Cancer 2019; 17:348-355.e5
Saad Fred, Carles Joan, Seger Monica, Reeves John, Wirth Manfred, Miller Kurt, Nilsson Sten, O'Sullivan Joe M, Keizman Daniel, Heinrich Daniel, Gillessen Sommer Silke, Heidenreich Axel
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
Heidenreich A, Nilsson S, Seger M, Reeves J, Miller K, Wirth M, Carles J, O'Sullivan J, Keizman D, Heinrich D, Gillessen Sommer S, Saad F. Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program. BMC cancer 2019; 19:12.
Jan 7, 2019Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
Jan 7, 2019BMC cancer 2019; 19:12
Heidenreich Axel, Nilsson Sten, Seger Monica, Reeves John, Miller Kurt, Wirth Manfred, Carles Joan, O'Sullivan Joe M, Keizman Daniel, Heinrich Daniel, Gillessen Sommer Silke, Saad Fred
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial
Saad F, O'Sullivan J, Federhofer J, Wirth M, Tucci M, Petrenciuc O, Nilsson S, Miller K, Lévy J, Gratt J, Heinrich D, Heidenreich A, Gillessen Sommer S, Carles J. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol 2016; 17:1306-16.
Jul 26, 2016Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial
Jul 26, 2016Lancet Oncol 2016; 17:1306-16
Saad Fred, O'Sullivan Joe M, Federhofer Judith, Wirth Manfred, Tucci Marcello, Petrenciuc Oana, Nilsson Sten, Miller Kurt, Lévy Jérémy, Gratt Jeremy, Heinrich Daniel, Heidenreich Axel, Gillessen Sommer Silke, Carles Joan